Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK: XEN496 in pediatric KCNQ2-DEE
NCT04639310Phase 3Terminated
- Sponsor
- Xenon Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) comparing XEN496 with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Monthly (28 Day) Countable Motor Seizure Frequency at 12 weeks. Started Mar 2021; status: terminated.
02
Drugs
XEN496
03
Conditions
KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)
Beyond the preview
Go deeper on NCT04639310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639310.